Endocyte, Inc. is a West Lafayette, IN-based development-stage biopharmaceutical company focused on bringing targeted therapies for the treatment of cancer and inflammatory diseases to market.
The company’s pipeline candidate 177Lu-PSMA-617 is a first-in-class radioligand and therapeutic (RLT) that targets prostate-specific membrane antigen (PSMA). The company acquired exclusive worldwide rights to develop and commercialize 177Lu-PSMA-617 from ABX GmbH in October 2017. The candidate represents a more than $1 billion market opportunity and its development is now the main priority of the company.
Currently, the company plans to focus on its most promising programs - lutetium PSMA-617 radioligand therapy and prostate cancer, and CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform.
Endocyte’s earnings track record has been mixed so far. Over the four trailing quarters, the company has posted an average negative earnings surprise of 1.66%.
Currently, Endocyte has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Endocyte’s first-quarter 2018 loss was narrower-than-expected. The company posted a loss of 16 cents per share narrower than the consensus estimate of a loss of 19 cents.
Key Stats: The company finalized a phase III VISION trial design for177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA. The company also announced updated encouraging data on 30 patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617 from the ongoing phase II study. The data was published in The Lancet Oncology. The company expects an update at the American Society of Clinical Oncology (ASCO) Annual Meeting in June with early data on the additional 20 patients dosed in the expansion phase of that trial.
Share Price Impact: The shares were up almost 2.3% in pre-market trading.
Check back later for our full write up on ECYT earnings report later!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Image: Bigstock
Endocyte (ECYT) Posts Narrower than Expected Loss in Q1
Endocyte, Inc. is a West Lafayette, IN-based development-stage biopharmaceutical company focused on bringing targeted therapies for the treatment of cancer and inflammatory diseases to market.
The company’s pipeline candidate 177Lu-PSMA-617 is a first-in-class radioligand and therapeutic (RLT) that targets prostate-specific membrane antigen (PSMA). The company acquired exclusive worldwide rights to develop and commercialize 177Lu-PSMA-617 from ABX GmbH in October 2017. The candidate represents a more than $1 billion market opportunity and its development is now the main priority of the company.
Currently, the company plans to focus on its most promising programs - lutetium PSMA-617 radioligand therapy and prostate cancer, and CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform.
Endocyte’s earnings track record has been mixed so far. Over the four trailing quarters, the company has posted an average negative earnings surprise of 1.66%.
Currently, Endocyte has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Endocyte’s first-quarter 2018 loss was narrower-than-expected. The company posted a loss of 16 cents per share narrower than the consensus estimate of a loss of 19 cents.
Key Stats: The company finalized a phase III VISION trial design for177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA. The company also announced updated encouraging data on 30 patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617 from the ongoing phase II study. The data was published in The Lancet Oncology. The company expects an update at the American Society of Clinical Oncology (ASCO) Annual Meeting in June with early data on the additional 20 patients dosed in the expansion phase of that trial.
Share Price Impact: The shares were up almost 2.3% in pre-market trading.
Check back later for our full write up on ECYT earnings report later!
Endocyte, Inc. Price and EPS Surprise
Endocyte, Inc. Price and EPS Surprise | Endocyte, Inc. Quote
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>